Related Experiment Video
Updated: Jun 9, 2026

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
Published on: February 19, 2019
Long-term management of hepatitis C-seropositive subjects with AntiOxidant Biofactor (AOB), a fermented food
Myo-Khin1, Myat-Tin-Htwe-Kyaw, Yi-Yi-Kyaw
1Department of Medical Research-Lower Myanmar, No.5 Ziwaka Road, Yangon 11191, Myanmar.
Abstract:
The efficacy of AntiOxidant Biofactor (AOB) for the management of apparently healthy subjects with chronic hepatitis C infection was investigated. A total of 60 subjects (35 males, 25 females) participated in the trial. AOB was given orally in 2 packs (3 g per pack) 3 times per day. 17 subjects had taken AOB for 3 years, 31 subjects up to 2 years, and 41 subjects up to one year. The initial mean (SD) serum alamine aminotransferase (ALT) level was 46.3+/-35.4 IU/L, and significant (p0.05, paired t-test) reductions in the mean serum ALT levels were observed at 6 months (38.6+/-21.5 IU/L), 18 months (31.9+/-18.1 IU/L), 2 years (31.2+/-14.6 IU/L), and 3 years (28.0+/-15.9 IU/L). Those presenting with high serum ALT levels (30 subjects) demonstrated significant levels (p0.05, paired t-test) of reduction in the mean serum ALT levels at 6, 12, 18, 24, and 36 months of treatment. No side effects were observed and the AOB treatment was well tolerated by all subjects.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Chronic Pancreatitis II: Collaborative Care
Assessment:
Bioavailability Study Design: Healthy Subjects Versus Patients